![]() ![]() ![]() According to Gartner, “By 2018, digital drug launches will be the standard, with 80% of the top pharma companies announcing new products via at least five digital channels.” The moves have been made in reaction to the major changes the industry has undergone over the last few years, including digitalization, reduction in sales forces, evolving regulatory environment, and the changing needs of HCPs. This continues Indegene’s recent acquisition trend as the company acquired Aptillon for $4 million in 2012 and Total Therapeutics, an outcome research and clinical engagement services company, in 2014. The platform will be added to Indegene’s IP-based solutions, which help clients drive revenues and productivity by making transformational leaps in digitalization of customer engagement, health reform, healthcare cost reduction, and health outcomes improvement. Skura’s SFX platform is a global leader in adaptive sales enablement technology for life science organizations and delivers next-generation sales-enablement technology to help companies reach the right HCPs with the right message at the right time. We are excited to see Indegene add Syneos Health as another strategic collaborator in our joint mission to bring new value to life sciences and healthcare organizations,” said James Phillips, corporate vice president, Business Applications Group, Microsoft.Looking to expand its omnichannel software suite for life sciences product development capabilities in North America, Indegene acquired Skura Corporation’s life science business for $9 million. “Omnipresence is a good example of an industry-specific, multi-cloud solution built with and on Microsoft’s enterprise technologies working together in uniquely disruptive ways. “The next-generation solution will enable customers to harness data to provide actionable insights and realize better commercial experiences, with improved return on investment.” Omnipresence offers customers a bold new choice – an innovative platform, underpinned by Microsoft technologies, to drive intelligent commercial relationships,” said Alistair Macdonald, chief executive officer, Syneos Health. “The biopharmaceutical industry is under growing pressure to deliver value-based customer experiences in a far more competitive marketplace. Omnipresence is designed to deliver holistic, insights-driven experiences aligned with HCP needs and preferences to enable increased impact and satisfaction. Omnipresence works with life sciences and healthcare organizations to help drive intelligent customer relationships and experiences.īy activating healthcare professional (HCP) experiences, and unifying CRM and omnichannel technology together with advanced analytics and AI capabilities, the platform aims to improve upon traditional CRM or multichannel technologies that focus on singular and disparate engagements. The Omnipresence platform is the result of a strategic alliance with Indegene, a global healthcare tech firm, which brings together Microsoft Power Platform, Dynamics 365, Azure, Office 365 including Teams, LinkedIn and Microsoft AI into a unified customer experience management (CXM) platform for the healthcare industry. ![]() ![]() Syneos Health has entered a strategic collaboration with Indegene Omnipresence and has made a minority investment in the company’s next-generation unified customer experience platform. ![]()
0 Comments
Leave a Reply. |